Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple-dose halazepam kinetics.

M Chung, J M Hilbert, R P Gural

    Clinical Pharmacology and Therapeutics
    |June 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Feeding the cosmos: tackling personalized space nutrition and the leaky gut challenge.

    NPJ microgravity·2025
    Same author

    Experimental Observation of the Motion of Ions in a Resonantly Driven Plasma Wakefield Accelerator.

    Physical review letters·2025
    Same author

    Application of a mathematical framework for the optimization of precision-fed dairy cattle diets.

    Animal : an international journal of animal bioscience·2024
    Same author

    Vaccine-induced NA immunity decreases viral shedding, but does not disrupt chains of airborne transmission for the 2009 pandemic H1N1 virus in ferrets.

    mBio·2024
    Same author

    Knowledge, Perception and Confidence in Performance on Infection Prevention and Control Measures among the Nursing Students.

    Kathmandu University medical journal (KUMJ)·2024
    Same author

    Filamentation of a relativistic proton bunch in plasma.

    Physical review. E·2024
    Same journal

    Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation.

    Clinical pharmacology and therapeutics·2026
    Same journal

    From Executor to Orchestrator: The Pharmacology Scientist in the Age of Agentic AI.

    Clinical pharmacology and therapeutics·2026
    Same journal

    The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

    Clinical pharmacology and therapeutics·2026
    See all related articles

    This study evaluated the pharmacokinetics of halazepam and its metabolite N-desalkylhalazepam in healthy men. Steady-state levels were predictable and reached within days, informing anxiety disorder treatment.

    Area of Science:

    • Pharmacology
    • Clinical Pharmacokinetics

    Background:

    • Halazepam is a benzodiazepine prescribed for anxiety disorders.
    • Understanding its steady-state kinetics is crucial for effective therapeutic use.

    Purpose of the Study:

    • To evaluate the steady-state pharmacokinetics of halazepam.
    • To assess the kinetics of its primary active metabolite, N-desalkylhalazepam.

    Main Methods:

    • Eleven healthy male participants received 40 mg of oral halazepam every 8 hours for 14 days.
    • Plasma concentrations of halazepam and N-desalkylhalazepam were quantified using gas chromatography.

    Main Results:

    • Halazepam's kinetics fit a two-compartment open model with first-order absorption.
    • Elimination half-lives were 34.7 hours for halazepam and 57.9 hours for N-desalkylhalazepam.

    Related Experiment Videos

  • Steady-state levels were achieved by day 3 for halazepam and day 11 for N-desalkylhalazepam.

    • Conclusions:

    • Steady-state concentrations of halazepam and N-desalkylhalazepam are predictable.
    • Kinetic data supports the dosing regimen for managing anxiety disorders with halazepam.